Arcutis Biotherapeutics (ARQT) 2026 meeting OKs directors, auditor and executive pay
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Arcutis Biotherapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. Stockholders of record as of April 8, 2026, when 125,073,249 common shares were outstanding, were entitled to vote.
All three proposals were approved. Three Class III directors were elected to serve until the 2029 annual meeting, with support ranging from about 62.8 million to 75.8 million votes for each nominee, plus broker non-votes. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
On a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers with about 88.7 million votes for, 3.7 million against, and 0.8 million abstentions. The Board also approved revisions to the Amended and Restated Non-Employee Director Compensation Program, effective as of the Annual Meeting, updating cash and equity compensation for non-employee directors.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.07, 8.01, 9.01
3 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Shares entitled to vote: 125,073,249 shares
Votes for auditor ratification: 107,867,442 votes
Executive pay advisory approval: 88,728,269 votes for
+3 more
6 metrics
Shares entitled to vote
125,073,249 shares
Common stock outstanding as of April 8, 2026 record date
Votes for auditor ratification
107,867,442 votes
For Ernst & Young LLP as 2026 independent auditor
Executive pay advisory approval
88,728,269 votes for
Non-binding advisory vote on named executive officer compensation
Director vote – Watanabe
75,771,853 votes for
Election of Class III director Todd Franklin Watanabe
Director vote – Krishnamohan
74,956,903 votes for
Election of Class III director Neha Krishnamohan
Director vote – Heron
62,830,439 votes for
Election of Class III director Patrick J. Heron
Key Terms
broker non-votes, non-binding advisory basis, independent registered public accounting firm, Amended and Restated Non-Employee Director Compensation Program, +1 more
5 terms
broker non-votes financial
"Nominee | Votes for | Votes withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding advisory basis financial
"Approval, on a non-binding advisory basis of the compensation of the Company’s named executive officers"
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
independent registered public accounting firm financial
"Ernst & Young LLP, as the independent registered public accounting firm of the Company"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Amended and Restated Non-Employee Director Compensation Program financial
"revisions to the Arcutis Biotherapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Arcutis Biotherapeutics (ARQT) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing three Class III directors, ratifying Ernst & Young LLP as independent auditor for 2026, and approving, on a non-binding advisory basis, compensation for named executive officers. All three proposals received sufficient support and were approved at the meeting.
Were all Arcutis Biotherapeutics (ARQT) director nominees elected in 2026?
Yes. All three Class III director nominees—Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe—were elected to serve until the 2029 annual meeting or until successors are chosen. Each nominee received tens of millions of votes in favor, plus broker non-votes.
Did Arcutis (ARQT) stockholders approve executive compensation on an advisory basis?
Yes. Stockholders approved the compensation of Arcutis’ named executive officers on a non-binding advisory basis, with 88,728,269 votes for, 3,723,408 against, and 824,860 abstentions, along with 14,868,017 broker non-votes recorded on this proposal.
Which auditor did Arcutis Biotherapeutics (ARQT) ratify for fiscal year 2026?
Stockholders ratified the selection of Ernst & Young LLP as Arcutis’ independent registered public accounting firm for the fiscal year ending December 31, 2026, with 107,867,442 votes for, 15,748 against, and 261,364 abstentions recorded on the proposal.
What change did Arcutis (ARQT) make to non-employee director compensation in 2026?
The Board approved revisions to the Amended and Restated Non-Employee Director Compensation Program, effective as of the Annual Meeting. The program provides annual cash and equity compensation for eligible non-employee directors, with detailed terms set out in Exhibit 10.1 to the report.